Ben Franklin Technology Partners of Southeastern Pennsylvania

Ben Franklin Technology Partners of Southeastern Pennsylvania is a non-profit organization established in 1982 that serves as a vital capital provider and supporter of technology development in the region. Based in Philadelphia, it has invested over $170 million in more than 2,000 early-stage and established technology companies, fostering innovation primarily in information technology, health, and physical sciences. The organization not only provides financial support but also develops partnerships between universities and industries to accelerate the commercialization of scientific discoveries. By strengthening the local entrepreneurial ecosystem, Ben Franklin Technology Partners plays a crucial role in job creation and economic transformation in Southeastern Pennsylvania.

Jonathan Beschen

Investment Director, Information Technology Investment Group

Anthony George

Analyst

Mark de Grandpre

Investor

Kevon Gray

Analyst

Roze McDevitt

Analyst

Adare McMillan

CFO

Omar Mencin

Managing Director, Information Technology Investment Group

Kathie Jordan Ph.D

Managing Director, Healthcare Investment Group

Past deals in DRM

DrayNow

Series A in 2020
DrayNow, Inc., founded in 2017 and based in Pipersville, Pennsylvania, operates as a technology company specializing in the intermodal freight sector. It offers a real-time online marketplace that connects intermediaries with carriers, facilitating the efficient management of intermodal freight transportation. By leveraging advanced technology, DrayNow enables users to maintain constant visibility of shipments, compare rates, view load details, and select available loads in real-time. This innovative platform optimizes the first and last mile of intermodal logistics, enhancing operational efficiency and helping companies achieve higher levels of capacity, service, and profitability.

Relmada Therapeutics

Series A in 2012
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company based in New York that focuses on developing innovative treatments for central nervous system (CNS) diseases and chronic pain management. The company's lead product candidate, d-Methadone, is currently undergoing Phase II clinical trials for conditions such as depression and neuropathic pain. In addition to d-Methadone, Relmada is also working on LevoCap ER, an abuse-resistant formulation of levorphanol; BuTab, an oral version of buprenorphine; and MepiGel, a topical formulation of mepivacaine designated for orphan drug status. Founded in 2004, Relmada aims to address significant unmet medical needs within the pain management and CNS therapeutic areas through its diversified portfolio of drug candidates.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.